Beyond Spx-Published 30/7/2024-Extract:DAYBUE Opportunity"DAYBUE...

Beyond Spx-Published 30/7/2024-Extract:
DAYBUE Opportunity
"DAYBUE represents a significant growth opportunity for ACADIA. In its first year on the market, DAYBUE has already captured approximately 25% of the diagnosed Rett syndrome patient population in the U.S. ACADIA sees substantial room for further growth, as there are an estimated 6,000 to 9,000 Rett syndrome patients in the U.S., with the majority still not on treatment.ACADIA is focused on driving continued adoption of DAYBUE by leveraging real-world evidence of the product’s benefits, improving GI management strategies, and building on the strong persistency rates observed so far. The company is also making progress in expanding DAYBUE’s availability globally, with regulatory filings underway in Europe and Japan."
Kens